USPTO serial 88847647
PB PHASEBIO
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LEIPZIG, MARC J
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PB PHASEBIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brendan J. Hughes
Brendan J. Hughes COOLEY LLP1299 PENNSYLVANIA AVENUE, NW, SUITE 700WASHINGTON, DC 20004UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for treating heart disease, heart conditions, hypertension, pulmonary hypertension, and other disorders of the cardiopulmonary system; pharmaceutical preparations for treating orphan diseases, namely, cystic fibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy, achondroplasia, short bowel syndrome, hypoparathyroidism, systemic lupus erythematosus, insulin-like growth factor deficiency, growth hormone deficiency; pharmaceuticals comprising drugs based on recombinant Elastin-like polypeptides technology platform, namely, pharmaceuticals for treating heart disease, heart conditions, hypertension, pulmonary hypertension, other disorders of the cardiopulmonary system, and orphan diseases, namely, cystic fibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy, achondroplasia, short bowel syndrome, hypoparathyroidism, systemic lupus erythematosus, insulin-like growth factor deficiency, growth hormone deficiency; pharmaceutical preparations consisting of reversal agents for counteracting the effects of platelet aggregation inhibitors | ACTIVE | — |
| 042 | Medical and scientific research services, namely, medical research; medical and scientific research services all in the field of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PhaseBio Pharmaceuticals, Inc.
- Other trademarks owned by PhaseBio Pharmaceuticals, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named PB PHASEBIO
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 16, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 16, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 23, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 22, 2023 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Mar 22, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 10, 2023 | EXT5 | SOU EXTENSION 5 FILED | — |
| Mar 10, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 7, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Sep 15, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 13, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Sep 13, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Sep 13, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 18, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 16, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 16, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 16, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 15, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 13, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 13, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 13, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 17, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 15, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 15, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 15, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 15, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 28, 2020 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Aug 25, 2020 | APET | ASSIGNED TO PETITION STAFF | — |
| Jul 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 21, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 1, 2020 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Jul 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 17, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 16, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 1, 2020 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Mar 31, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 28, 2020 | NWAP | NEW APPLICATION ENTERED | — |